What Longidaza Treats: Main Uses and Benefits

Longidaza contains the enzyme bovhyaluronidase azoximer, which is relevant in contexts marked by increased discomfort or tension associated with connective tissue changes. Its use is considered relevant in clinical settings where supportive symptom management is appropriate for conditions associated with scar tissue formation.

It is applied across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort, such as conditions involving inflammatory or irritative processes, or those marked by increased physiological stress. The medicine is often used when symptoms intensify and supportive relief is needed, helping to address symptom clusters that may become intense or disruptive.

“It helps address symptoms that interfere with daily comfort and contributes to improved day-to-day comfort during symptomatic periods.”

This therapeutic support helps ease the overall symptom burden by assisting with maintaining functional stability and enabling patients to cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Functional Strain

This treatment is commonly used to help with symptoms that create noticeable physiological strain or symptoms that interfere with daily functioning.

Regulatory References

1. Ministry of Health of the Russian Federation Approved Label

Eligibility Map: Who can and cannot use Longidaza

The eligibility profile for Longidaza (Bovhyaluronidaze Azoximer) is defined by official regulatory documentation, which outlines strict criteria for use based on patient age, clinical status, and physiological state.

Eligibility Scope	Status
Populations Allowed	Adults and adolescents over 18 years of age.
Populations Contraindicated	Patients with malignant neoplasms, acute renal failure, pulmonary hemorrhage, recent vitreous hemorrhage, or hypersensitivity to the drug.

Official Eligibility Statements

• Age-Related Rules: The medicine is contraindicated in individuals under 18 years of age because official data on its safety and efficacy are not available for this group.
• Physiological State: Use is absolutely contraindicated during pregnancy and the breastfeeding period.
• Condition-Specific Restrictions: Patients with acute infectious conditions must not use the medicine unless it is co-administered with specific antimicrobial therapy.
• Conditional Use: The use of Longidaza must be with caution and restricted to no more than once a week for patients with chronic renal failure or a history of pulmonary hemorrhage.

The regulatory profile establishes who may use the medicine and who must be excluded, with an absolute contraindication being the highest severity classification for non-eligibility.

Interactions with other medicines and products

Official regulatory documentation for Bovhyaluronidaze Azoximer (Longidaza) describes several interactions that modify the exposure or effect of co-administered substances. The primary mechanism involves pharmacokinetic modification, specifically the increase in absorption and dispersion of medicinal products when co-administered by subcutaneous or intramuscular injection.

Documented Interaction Patterns

Interaction Type	Interacting Substances/Classes	Interaction Outcome (as per official documents)
Exposure Modification	Parenteral Medications, Antibacterial Drugs	Documented increase in absorption and bioavailability of the co-administered drug.
Pharmacodynamic Reinforcement	Local Anesthetics	Documented acceleration of the anesthetic effect.
Pharmacodynamic Risk	Anticoagulants, Antiplatelet Drugs	Caution advised due to a documented increased risk of localized bleeding.
Enzyme Inhibition	High Doses of Vitamin C, Reducing Agents	Documented inhibition of the drug’s enzymatic activity.

These interactions shape the product's official profile, noting substances that either experience enhanced exposure (like antibacterial agents) or present an increased risk when combined (like anticoagulants). No warnings are documented regarding interactions mediated by CYP-enzymes or drug transporters. There are no mandatory time-separation rules specified in the regulatory text.

How Longidaza Works

Longidaza (Bovhyaluronidaze Azoximer) acts through an integrated mechanism involving structural breakdown and environmental modulation to modulate the structure of abnormal connective tissue.

---

Enzymatic Breakdown of the Extracellular Matrix

The primary action involves the Bovhyaluronidase component, which acts as a specific enzyme to chemically break down (hydrolyze) the large Glycosaminoglycans (GAGs), particularly Hyaluronic Acid (HA), that form the dense structure of the abnormal connective tissue matrix. This molecular cleavage reduces the viscosity and density of the matrix, initiating a cascade that leads to increased tissue permeability and fluid diffusion.

---

Modulation of Tissue Stiffness and Fluid Dynamics

The depolymerization of HA and other GAGs drives a major physiological shift by reducing the resistance to fluid flow within the tissue. This results in the modulating of tissue stiffness and results in the structural modulation and resorption of fibrous formations, exerting an effect on the physical properties of abnormal connective tissue.

---

Sustained Action and Immunomodulatory Support

The Azoximer polymer component provides two crucial functions: it protects the enzyme from rapid inactivation, ensuring a sustained local hydrolytic mechanism, and it actively modulates the tissue microenvironment. This support includes an anti-inflammatory effect that suppresses the chronic signaling and oxidative stress that promotes abnormal connective tissue development.

How to Use Longidaza

The administration of Longidaza (Bovhyaluronidaze Azoximer) is based on a structured, course-limited protocol. The medicine is supplied as a lyophilizate for injection and as 3000 IU suppositories, permitting multiple routes of use.

Administration Routes and Dosing

Administration routes include parenteral injection (subcutaneous (SC) or intramuscular (IM)), rectal, vaginal, and external/topical application (such as in conjunction with ultraphonophoresis). The standard dose for administration is 3000 IU per dose, regardless of the form. Treatment follows an intermittent, non-daily schedule; for instance, a common regimen involves administering 3000 IU intramuscularly once every five days.

Treatment is typically delivered in finite courses, with total administrations ranging from 5 to 25 doses. A repeat course is recommended no earlier than three months after the completion of the initial regimen.

Preparation and Procedural Rules

Specific instructions govern the preparation of the injectable form. The lyophilizate must be dissolved in a small volume (e.g., 1.0 to 2.0 mL) of a specific solvent, such as 0.5% procaine solution or 0.9% sodium chloride solution. The solvent must be added slowly, and the vial must be stirred gently without shaking to prevent protein foaming; the prepared solution is not storable. Suppositories are generally administered at night. Furthermore, use is procedurally restricted in certain groups; for patients with chronic renal failure, the maximum allowed frequency is once per week. The medication must not be administered intravenously.

Longidaza: Recent Clinical Evidence

Evidence for Use in Post-COVID-19 Pulmonary Sequelae

The primary evidence was evaluated in a large-scale, Randomized, Double-blind, Placebo-controlled Trial (RCT) exploring the clinical setting of lingering lung changes following COVID-19 infection in adults. Researchers examined functional measures like Forced Vital Capacity (FVC) and patient-reported outcomes, including dyspnea (shortness of breath) and oxygen saturation. Study reports described that outcomes related to the primary functional measure, FVC, were mixed across the overall observed populations. However, research describes patterns observed in the study period related to patient-reported experiences like exertional desaturation. The fact that the FVC findings were mixed contributes to the uncertainty regarding changes to the underlying lung function across all patients studied.

---

Evidence for Use in External Genital Endometriosis

Research for this condition is primarily derived from prospective, non-randomized, non-interventional observational studies. These studies included adult female patients receiving standard hormonal therapy, and research observed patient-reported outcomes describing perceived discomfort, such as pelvic pain severity. The non-randomized study design means the evidence provides limited certainty, and comparative evidence is lacking that can confidently isolate the specific influence of Longidaza.

---

Evidence for Use in Chronic Prostatitis and BPH

Research was conducted for chronic nonbacterial prostatitis and Lower Urinary Tract Symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) using various designs, including open-label, randomized controlled studies. The studies evaluated patient-reported outcomes and functional measures like maximum urine flow rate (Qmax). Certainty remains low for some of these applications because some available trials were open-label, which can introduce bias when measuring subjective outcomes.

---

Long-Term Studies and Extended Follow-up Data

The research available generally provides insight into short-term changes over observation intervals typically under six months (180 days). Long-term effects are not fully established regarding sustained or permanent changes. Specifically, there is limited information on whether or how observed patterns in measured symptom outcomes or functional measures persist years after the preparation is discontinued.

---

Evidence in Specific Patient Groups and Subpopulations

The majority of published research was evaluated in adults. Specific studies have included detailed subgroup analyses for older adults and those with comorbidities. However, data for certain groups, such as the pediatric population (children and adolescents) or those who are pregnant, remain insufficient.

Key Studies & References

1. Ministry of Health of the Russian Federation Approved Label (Longidaza Suppositories)

Common questions about Longidaza (FAQ)

Q: Does Longidaza have anti-inflammatory effects according to official documents?

Official regulatory documents describe that the Azoximer carrier component of the medicine retains specific biological activities, including both anti-inflammatory and immunomodulating effects.

Q: How quickly does Longidaza start working after administration?

Pharmacokinetic studies, which track how the body processes the drug, indicate that following an injection, the medicine is rapidly absorbed into the systemic circulation. It reaches its peak concentration in the bloodstream within approximately 20 to 25 minutes after administration.

Q: What is the expected duration of action for Longidaza?

Official information explains that the chemical structure of the drug, which involves the covalent conjugation of the enzyme and the polymer, is designed to increase resistance to inhibitors. This engineering is described as leading to a prolonged duration of action compared to native hyaluronidase enzymes.

Q: Are there specific vitamins or supplements that are known to interact with Longidaza?

Official documents describe that co-administration with high doses of Vitamin C, also known as ascorbic acid, may result in the inhibition of the drug’s enzymatic activity.

Q: Does Longidaza affect bone repair or the healing process after surgery?

Non-clinical data cited in official regulatory documents describes that the use of the drug during or after surgical procedures does not cause worsening of the post-operative period. Furthermore, studies indicate it does not delay the process of bone tissue repair.

Q: What is the main function of the 'azoximer' part of the drug compound?

The Azoximer polymer component serves two primary functions. It helps protect the active enzyme from rapid inactivation, which ensures a more prolonged activity in the body. Additionally, it is described as having specific biological properties, including chelating, antioxidant, anti-inflammatory, and immunomodulatory properties.

Q: What are the requirements for storing Longidaza at home?

Storage requirements vary by formulation. The lyophilized powder (for injection solution) must be stored under refrigeration, specifically between 2 C and 8 C, and protected from light. Suppositories, on the other hand, should be stored below 15 C and must not be frozen.

Q: Is Longidaza used for treating scar tissue or fibrosis?

Official regulatory indications describe its use in the treatment of various forms of scars, such as keloid and hypertrophic scars, and those forming after trauma, burns, or surgery. The drug's antifibrotic effect has also been studied experimentally in models of specific types of tissue fibrosis.

Q: Does Longidaza have any approved uses in the field of cosmetology or dermal fillers?

Official indications for use include certain treatments within dermatovenerology and cosmetology. These uses involve the treatment of specific types of scars and conditions such as localized scleroderma.

Q: What research evidence supports the use of Longidaza for fibrotic conditions?

The drug's core antifibrotic action has been demonstrated experimentally in laboratory studies using a model of pneumofibrosis. Additionally, clinical trials have examined its use in human conditions involving fibrotic changes, such as post-COVID pulmonary sequelae.

Q: Are there studies examining Longidaza's use in patients with residual changes after COVID-19?

A randomized, double-blind, placebo-controlled clinical study was conducted with the objective of evaluating the medicine's efficacy and safety in adult patients experiencing residual changes in the lungs following COVID-19 infection.

Q: Is Longidaza a generic drug, or is it a specific formulation?

Longidaza is described in official product information as an original pharmaceutical preparation. It is a semi-synthetic covalent conjugate, which means its unique chemical structure differentiates it from generic or native hyaluronidase products.

Q: What are the warnings associated with using Longidaza near areas of inflammation or infection?

Official safety data indicates the drug is contraindicated in acute systemic infectious diseases unless it is co-administered with specific antimicrobial therapy. Non-clinical safety data suggests that the therapeutic use of the drug does not cause worsening of an infectious process.

Q: What is the half-life of Longidaza in the body after administration?

While a specific half-life value is not always provided, pharmacokinetic data describes the drug's process in the body. It is rapidly absorbed following injection, and the carrier component breaks down into low molecular weight compounds that are excreted primarily via the kidneys in a two-phase process.

Q: Does Longidaza suppress the immune system?

Official safety data describes the drug as a practically non-toxic compound that does not impair the normal functioning of the immune system. The drug is instead classified as having immunomodulatory activity, meaning it helps to regulate the immune response.

Q: Is there any evidence suggesting Longidaza has a prolonged action compared to other hyaluronidase products?

Official documents describe that the unique covalent conjugation of the enzyme in Longidaza results in an increased resistance to inhibitors in the body. This structural enhancement is described as leading to a prolonged duration of action compared to that of native hyaluronidase enzymes.

Q: Are there specific organ systems, like the kidneys, where caution is advised with Longidaza use?

Yes, official eligibility guidelines advise caution for patients with chronic renal (kidney) failure, where administration frequency must be limited. Furthermore, the drug is absolutely contraindicated in cases of acute renal failure.

Q: Does using Longidaza increase the body's antibody response or resistance to infection?

Official documents describe that the drug can regulate inflammatory mediators and is able to increase the body's humoral immune response. This action contributes to increasing the body's natural resistance to infection.

Q: Is Longidaza sometimes used in combination with physiotherapy procedures?

Yes, official administration instructions for the lyophilized powder describe its use in conjunction with physical procedures. Specific procedures mentioned include photophoresis and ultraphonophoresis.

Q: Does Longidaza help to suppress the synthesis of components of connective tissue?

Official documents describe that the drug is able to bind specific ions, such as iron ions, in the body. By binding these ions, it is described as suppressing the reverse reaction in the body that is aimed at the synthesis of components of connective tissue.

Q: Are there any known effects of Longidaza on a patient's quality of life based on clinical trials?

Yes, clinical trials have utilized standardized measures to assess changes in patient well-being. For example, studies have used the European Quality of Life 5-Dimension 5-Level Questionnaire (EuroQol-5D-5L) to assess changes in patient quality of life.

Q: Are there specific organ systems, like the lungs, where caution is advised with Longidaza use?

The drug is explicitly contraindicated in patients with specific active bleeding issues related to the lungs, such as pneumorrhagia (pulmonary hemorrhage) and haemoptysis (coughing up blood).

Q: What are the main goals of the Longidaza research studies that have been published?

The main objectives of published studies generally involve evaluating the drug's efficacy and safety in specific patient populations and conditions. For example, a key objective was to prove the superiority of the drug over placebo in adult patients with post-COVID respiratory changes based on the dynamics of respiratory function.

Q: Does Longidaza have effects on breathing or pulmonary function in study populations?

Yes, clinical studies, such as those related to post-COVID sequelae, have included the evaluation of both objective and subjective indicators of pulmonary function. These measures include changes in Forced Vital Capacity (FVC) and subjective measures like the severity of dyspnea (shortness of breath).

Q: Does Longidaza improve the efficacy of pain-relieving medicines (analgesics)?

Official documents describe a known drug interaction where co-administration with local anesthetics can accelerate or enhance the anesthetic effect.

Q: Why is Longidaza sometimes mentioned with chronic pelvic conditions like prostatitis?

The drug is officially indicated in urology for the combination treatment of chronic prostatitis and interstitial cystitis. This is why it is often mentioned in discussions related to these specific chronic pelvic conditions.

How to Store and Dispose of Longidaza

The required storage conditions for Longidaza (Bovhyaluronidaze Azoximer) vary strictly by formulation, as specified in regulatory labeling.

---

Storage Requirements

Formulation	Temperature Requirement	Additional Protection
Lyophilized Powder	Store between 2 C and 8 C (refrigerated).	Protected from light and moisture (dry place).
Suppositories	Store below 15 C. Do not freeze.	Protected from light.

The drug must be stored out of the reach and sight of children. The lyophilized powder must be reconstituted and used immediately; the prepared solution is not intended for storage.

Disposal Instructions

Do not use the product after its labeled expiration date or if the packaging is damaged. Unused or expired Longidaza must not be discarded in household waste or flushed down the toilet. Disposal must follow specialized local regulations for pharmaceutical waste.